Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 40 recruiting now official registry

Anatomic Stage II Breast Cancer AJCC v8 clinical trials

40 of 74 indexed Anatomic Stage II Breast Cancer AJCC v8 trials are currently recruiting.

74 US clinical trials · 40 currently recruiting

Anatomic Stage II Breast Cancer AJCC v8 is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 40 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.

The research picture

Anatomic Stage II Breast Cancer AJCC v8 has 74 registered US clinical trials, 40 of them open to new participants right now, about 54% of the total.

40
recruiting participants now
54%
of trials open to enrollment
9
in Phase 3–4 (later-stage)
12
top sponsor: M.D. Anderson Cancer Center
Phase 18Phase 218Phase 38Phase 41

Active & Recent Trials

74 total, page 1 of 2

RECRUITING Phase 3 3,680 participants

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

NCT06058377

RECRUITING Phase 3 2,400 participants

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

SWOG Cancer Research Network

NCT05929768

RECRUITING Phase 3 1,524 participants

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Alliance for Clinical Trials in Oncology

NCT06876714

RECRUITING 1,300 participants

Breast Cancer Survivorship Biorepository

University of Southern California

NCT05786664

RECRUITING Phase 3 1,295 participants

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Alliance for Clinical Trials in Oncology

NCT05812807

RECRUITING NA 640 participants

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

Fred Hutchinson Cancer Center

NCT05930483

RECRUITING 250 participants

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

University of Southern California

NCT07259304

RECRUITING 230 participants

Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

Mayo Clinic

NCT04517838

RECRUITING Phase 3 200 participants

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

City of Hope Medical Center

NCT06763328

RECRUITING Phase 2 174 participants

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

City of Hope Medical Center

NCT06042569

RECRUITING Phase 2 164 participants

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

Jonsson Comprehensive Cancer Center

NCT06113016

RECRUITING NA 160 participants

Breast Cancer, Reasoning, and Activity Intervention

Mayo Clinic

NCT04816006

RECRUITING NA 150 participants

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

Emory University

NCT06534125

RECRUITING Phase 2 120 participants

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

NCT06635980

RECRUITING NA 108 participants

Integrative Approaches for Cancer Survivorship (IACS3)

University of California, San Francisco

NCT06633926

RECRUITING 100 participants

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

Ohio State University Comprehensive Cancer Center

NCT07341503

RECRUITING Phase 2 88 participants

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Jonsson Comprehensive Cancer Center

NCT05595499

RECRUITING Phase 2 82 participants

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

City of Hope Medical Center

NCT06954831

RECRUITING Phase 2 75 participants

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

University of Michigan Rogel Cancer Center

NCT07158021

RECRUITING 70 participants

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

Mayo Clinic

NCT05417867

RECRUITING Phase 4 68 participants

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

University of Washington

NCT05183828

RECRUITING NA 60 participants

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT06582615

RECRUITING NA 55 participants

Neoadjuvant Breast Cancer Time Restricted Eating

Thomas Jefferson University

NCT05327608

RECRUITING Phase 2 51 participants

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vandana Abramson

NCT07016399

RECRUITING Early Phase 1 50 participants

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT05417308

RECRUITING NA 40 participants

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

University of Alabama at Birmingham

NCT05243056

RECRUITING NA 40 participants

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

Ohio State University Comprehensive Cancer Center

NCT05677802

RECRUITING Early Phase 1 40 participants

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Emory University

NCT05464810

RECRUITING Phase 2 38 participants

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Mayo Clinic

NCT07044310

RECRUITING Phase 2 36 participants

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

City of Hope Medical Center

NCT06538389

RECRUITING NA 30 participants

Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment

M.D. Anderson Cancer Center

NCT05928325

RECRUITING NA 30 participants

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Emory University

NCT05488145

RECRUITING NA 30 participants

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors

University of Alabama at Birmingham

NCT05452681

RECRUITING NA 27 participants

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Emory University

NCT05368428

RECRUITING Phase 2 25 participants

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

NCT04329065

RECRUITING 25 participants

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Mayo Clinic

NCT06401889

RECRUITING Phase 1 20 participants

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Mayo Clinic

NCT06999798

RECRUITING Phase 1 18 participants

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Emory University

NCT06324240

RECRUITING Phase 1 18 participants

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

NCT05319873

RECRUITING NA 15 participants

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

M.D. Anderson Cancer Center

NCT02918474

ACTIVE NOT RECRUITING Phase 2 2,175 participants

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

ECOG-ACRIN Cancer Research Group

NCT04266249

ACTIVE NOT RECRUITING 1,410 participants

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer

M.D. Anderson Cancer Center

NCT04678414

ACTIVE NOT RECRUITING 1,336 participants

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

SWOG Cancer Research Network

NCT03939481

ACTIVE NOT RECRUITING Phase 3 1,167 participants

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Alliance for Clinical Trials in Oncology

NCT04379570

ACTIVE NOT RECRUITING Phase 2 1,100 participants

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

M.D. Anderson Cancer Center

NCT01334021

ACTIVE NOT RECRUITING Phase 3 1,056 participants

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Alliance for Clinical Trials in Oncology

NCT04457596

ACTIVE NOT RECRUITING NA 565 participants

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

SWOG Cancer Research Network

NCT05568472

ACTIVE NOT RECRUITING NA 543 participants

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

Alliance for Clinical Trials in Oncology

NCT04549571

ACTIVE NOT RECRUITING NA 400 participants

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

Ohio State University Comprehensive Cancer Center

NCT04906200

ACTIVE NOT RECRUITING NA 332 participants

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Thomas Jefferson University

NCT04086875

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 18
Phase 3 8
Phase 4 1

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Anatomic Stage II Breast Cancer AJCC v8 Trial Landscape

74 indexed Anatomic Stage II Breast Cancer AJCC v8 studies · 40 recruiting (54%).

Phase mix: 9 late (III/IV) vs 26 early (I/II).

Top sponsor: M.D. Anderson Cancer Center (12 trials), 9 others listed. 50 shown below, recruiting first.

How to read this condition's trial landscape

That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Anatomic Stage II Breast Cancer AJCC v8?

PlainTrial tracks 74 US clinical trials for Anatomic Stage II Breast Cancer AJCC v8, of which 40 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Anatomic Stage II Breast Cancer AJCC v8?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.